Bart Neyns

30PUBLICATIONS
98CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsNanomedicineApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (30)

|May 26, 2026
Reinvigorating the Cancer-Immunity Cycle by Intratumoral Administration of Conventional Dendritic Cells in Melanoma and Other Solid Tumors: A Narrative Review.

|May 04, 2026
Discontinuation of combo immunotherapy and outcome of patients with melanoma brain metastases.

|Mar 14, 2026
The Effectiveness of a Multidisciplinary Integrative Survivorship Program for Cancer-Related Cognitive Impairment: A Prospective Cohort Study.

Nathalie Vanlaer, Camille Testaferrata, Lynn Decabooter

|Dec 17, 2024
Regorafenib Combined with BRAF/MEK Inhibitors for the Treatment of Refractory Melanoma Brain Metastases.

Iris Dirven, Eden Pierre, An-Sofie Vander Mijnsbrugge

|Oct 07, 2024
Phase II Clinical Trial of Trametinib and Low-Dose Dabrafenib in Advanced, Previously Treated <i>BRAF</i><sup><i>V600</i></sup><i>/NRAS</i><sup><i>Q61</i></sup> Wild-Type Melanoma (TraMel-WT).

Gil Awada, Iris Dirven, Julia Katharina Schwarze

|May 11, 2024
Emotional Distress, Cognitive Complaints, and Care Needs among Advanced Cancer Survivors Treated with Immune Checkpoint Blockade: A Mixed-Method Study.

Nathalie Vanlaer, Iris Dirven, Bart Neyns

Pageof 5

Frequent Collaborators

12 joint publications

Julia Katharina Schwarze

11 joint publications

Gil Awada

7 joint publications

Iris Dirven

6 joint publications

Anne Rogiers